Resources from the same session
LBA11 - IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)
Presenter: Nadia Harbeck
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
159O - Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group
Presenter: Vincent De Jong
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Webcast
160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Presenter: Andreas Schneeweiss
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA12 - PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
Presenter: Erica Mayer
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
161O - Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib
Presenter: Monica Arnedos
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA11, 159O and 160O
Presenter: Sherko Kümmel
Session: Proffered Paper - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Javier Cortés
Session: Proffered Paper - Breast cancer, early stage
Resources:
Webcast
Q&A and live discussion
Presenter: Javier Cortés
Session: Proffered Paper - Breast cancer, early stage
Resources:
Webcast